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The administration of dopaminergic medication to treat the symptoms of Parkinson’s 
disease (PD) is associated with addictive behaviors and impulse control disorders. Little 
is known, however, on how PD patients differ from other patients seeking treatments 
for behavioral addictions. The aim of this study was to compare the characteristics 
of behavioral addiction patients with and without PD. N  =  2,460 treatment-seeking 
men diagnosed with a behavioral addiction were recruited from a university hospital. 
Sociodemographic, impulsivity [Barratt Impulsiveness Scale (BIS-11)], and personality 
[Temperament and Character Inventory-Revised (TCI-R)] measures were taken upon 
admission to outpatient treatment. Patients in the PD group were older and had a higher 
prevalence of mood disorders than patients without PD. In terms of personality charac-
teristics and impulsivity traits, PD patients appeared to present a more functional profile 
than PD-free patients with a behavioral addiction. Our results suggest that PD patients 
with a behavioral addiction could be more difficult to detect than their PD-free coun-
terparts in behavioral addiction clinical setting due to their reduced levels of impulsivity 
and more standard personality traits. As a whole, this suggests that PD patients with a 
behavioral addiction may have different needs from PD-free behavioral addiction patients 
and that they could potentially benefit from targeted interventions.
Keywords: Parkinson’s disease, personality, impulsivity, behavioral addictions, gambling disorder, impulse control 
disorders
inTrODUcTiOn
Researchers and clinicians have identified that the administration of dopaminergic medication to ame-
liorate the symptoms of Parkinson’s disease (PD) is associated with impulse control disorders (ICDs) 
(1). These disorders vary greatly in their symptomatology and include the behavioral addictions: 
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gambling disorder, compulsive buying, and hypersexuality. 
Although prevalence studies are scarce, ICDs are thought to affect 
up to 16% of PD patients (2). Due to their clinical similarities with 
substance abuse disorders, many ICDs have been reclassified as 
behavioral addictions; and in the latest version of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5), gambling 
disorder was moved from the category of ICD to the new category 
of “Substance-Related and Addictive Disorders” (3).
The majority of studies examining PD patients with behavioral 
addictions have been cross-sectional, thereby greatly limiting 
the ability to reach meaningful conclusions regarding causal 
factors. One recent longitudinal study examining PD patients 
with an ICD over a 2-year span found that the prevalence of ICD 
behaviors remained relatively stable across observational period 
and that ICD-positive patients had more severe depression and 
reduced quality of life (4). Studies have identified that PD patients 
who develop behavioral addictions tend to be younger, more 
impulsive, and are more likely to have a personal or family history 
of alcohol abuse than PD patients without behavioral addictions 
(5, 6). High levels of impulsivity, which is understood to be 
modulated by dopaminergic transmission in the ventral striatum, 
may represent a risk factor for the development of behavioral 
addictions (7). One study comparing patients with PD to healthy 
controls found that both male gender and higher impulsivity 
scores, but not dose and kind of dopaminergic medications, 
were associated in PD with an increased probability of ICDs (8). 
Likewise, another study examining impulsivity traits in drug-
naïve patients found that elevated levels of attentional impulsive-
ness scores in PD patients screening positive for ICDs, leading the 
authors to suggest that these patients may possesses a subclinical 
pattern characterized by a reduced ability to focus on the task at 
hand (9). Contrastingly, the majority of studies in medicated PD 
patients report that, overall, PD patients tend to have lower levels 
of impulsivity compared to healthy controls (10). Significantly 
higher incidence of anhedonia and higher levels of impulsivity 
traits have also been found to coincide in patients with PD and 
an ICD, meaning that impairment of hedonic capacity coupled 
with higher impulsivity levels possibly might facilitate loss of 
control over reward-related behavior, thereby favoring the shift 
toward predominantly habit-based compulsive behaviors (11). 
Furthermore, both depression and anxiety symptoms have been 
found to be significantly correlated to impulsivity scores on the 
Barratt Impulsiveness Scale (BIS-11), indicating that PD patients 
with ICDs may be at higher risk for mood disorders (12).
Indeed, some authors have used the term “premorbid person-
ality” to characterize distinctive features of PD patients’ person-
ality traits, which are defined by a diminished desire to explore 
new environmental stimuli (“novelty seeking”) and higher levels 
of harm avoidance (10). Therefore, these patients would likely 
show a tendency toward inflexibility, low impulsivity levels, 
introspection, and cautiousness, and all this traits would remain 
after the manifestation of PD motor symptoms (13, 14). The few 
studies examining personality traits of PD patients with behav-
ioral addictions have found that these patients are more likely to 
show a tendency to lie and to have higher scores on cynicism and 
bizarre ideation (15), as well as lower levels of agreeableness and 
conscientiousness (16).
Addictive behaviors in PD patients are frequently under-
reported by both patients and caregivers (17). This fact poses 
a challenge for clinicians treating Parkinson’s patients with a 
behavioral addiction. To our knowledge, no studies to date have 
compared PD patients with behavioral addictions to PD-free 
patients with behavioral addictions. Clarifying the extent to which 
differences between these populations exist is needed to deter-
mine whether customized addiction treatment interventions are 
needed for PD patients. As such, the aim of the present study was 
to compare sociodemographic, personality, and impulsivity traits 
in patients seeking treatment for behavioral addictions with and 
without PD. By comparing behavioral addiction patients with and 
without PD, our findings could help make evident for behavioral 




A sample of 2,460 men diagnosed with a behavioral addiction 
from the Department of Psychiatry at Bellvitge University Hospital 
(Barcelona, Spain) between February 2004 and November 2014 
was considered. Exclusion criteria for the study were the presence 
of a mental disorder, intellectual disability, or active psychotic 
disorder. Only men were included in our analyses due to the lack 
of women seeking treatment at our Unit. Patients were screened 
via a structured interview by experienced clinical psychologists 
and psychiatrists before being included in the study sample. 
The sample of N = 2,460 patients was classified into two groups 
according to the presence/absence of PD (n = 32 with PD and 
n = 2,428 without PD).
Measures
We evaluated the presence of behavioral addictions with the 
following tools: patients were diagnosed with pathological gam-
bling if they met DSM-IV-TR criteria (18). All patient diagnoses 
were reassessed and recodified post  hoc and only patients who 
met DSM-5 criteria for GD were included in our analysis (3). 
Compulsive buying was assessed according to McElroy et  al.’s 
criteria (19), sexual addiction according to the sexual disorders 
not otherwise specified section (302.70) of the DSM-5 (3), and 
Internet gaming disorder according to Griffiths and Hunt (20) 
and DSM-5 (3) criteria.
Personality was assessed using the Temperament and Character 
Inventory-Revised (TCI-R) (21). This questionnaire is structured 
on seven primary dimension scores: four temperamental factors 
and three character dimensions. These different personality dimen-
sions have demonstrated adequate reliability-validity in the Spanish 
population with Cronbach’s alphas between 0.77 and 0.84 (22).
Lastly, impulsivity was measured using the BIS-11 (23). This 
includes 30 items rated on a four-point Likert scale. The validated 
Spanish version of this instrument (24) was used in this study.
additional Data
Demographic, clinical, and social/family variables were meas-
ured using a semi-structured, face-to-face clinical interview 
TaBle 1 | Description of the sample.





Age (years old) Mean-SD 41.8 13.5 41.5 13.4 61.7 6.94 <0.001*
Origin; n % Spanish 2,282 92.8% 2,250 92.7% 32 100.0% 0.112
Education level; n % Primary 1,866 75.9% 1,846 76.0% 20 62.5% 0.109
Secondary 444 18.0% 437 18.0% 7 21.9%
University 150 6.1% 145 6.0% 5 15.6%
Employment; n % Employed 1,420 57.7% 1,415 58.3% 5 15.6% <0.001*
Civil status; n % Single 824 33.5% 822 33.9% 2 6.3% 0.004*
Married 1,320 53.7% 1,296 53.4% 24 75.0%
Divorced 316 12.8% 310 12.8% 6 18.8%
*Bold: significant comparison (0.05 level).
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(25). Some of the variables covered were behavioral addiction 
duration, current pharmacological treatment, and psychiatric 
comorbidities.
Procedure
Parkinson’s disease patients were first diagnosed by a neu-
rologist and then derived to the Department of Psychiatry at 
our University Hospital in order to receive evaluation regarding 
behavioral addiction options. Patients individually completed 
the questionnaires required for this study before initiating out-
patient treatment. If patients were unable to complete the evalua-
tion on their own (e.g., due to being illiterate), these instruments 
were administered by a clinician. Somatic comorbidities and 
psychopharmacological treatments were assessed, especially in 
the case of dopamine replacement therapy and psychotropic 
drugs.
statistical analysis
Statistical analysis was carried out with SPSS20 for windows. Chi-
square (χ2) tests compared categorical variables between patients 
with and without PD. Analysis of variance (ANOVA) adjusted 
for patients’ age and behavioral addiction subtype compared the 
quantitative clinical variables. The effect size for the proportions 
and means comparisons was estimated through Cohen’s-d coef-
ficient, considering |d| >  0.50 to be a moderate effect size and 
|d| > 0.80 to be a high effective size. Bonferroni–Finner’s correc-
tion was applied to control Type-I error due to multiple statistical 
comparison.
resUlTs
Descriptive for the sample
Table 1 displays a description of the study sample and the groups 
with and without PD. Significant differences were found between 
participants with and without PD with regards to age, employ-
ment status, and civil status (patients in the PD group were 
older and had a higher proportion of married subjects). Table S1 
in Supplementary Material contains the prevalence of other 
behavioral addictions in the sample. Table S2 in Supplementary 
Material lists the medication being taken by the n = 32 patients 
diagnosed with PD. The duration of PD for this group was 
7.7 years (SD = 5.5).
comparison of Patients with  
and without PD
Table 2 contains a comparison of the clinical variables between 
the patients with and without PD. Adjusted for the covariates age 
and behavioral addiction subtype, the presence of PD was associ-
ated with a lower prevalence of substances use/abuse (tobacco, 
alcohol, and other drugs), lower levels in impulsivity (except for 
on the BIS-11 motor scale) and higher levels in the personality 
traits of reward dependence, self-directedness, and cooperative-
ness. Patients with PD also presented a higher prevalence of 
mood disorders than patients without PD.
DiscUssiOn
This study analyzed the specific sociodemographic, impulsiv-
ity, and personality features of PD patients with addictions 
compared to PD-free patients with addictions. It was our aim to 
provide behavioral addiction clinicians with a clearer picture of 
the features that distinguish these two groups from each other. 
Regarding sociodemographic variables, age greatly differed 
between both groups, with older ages being found in the PD 
group. This finding dovetails with several studies reporting that 
the PD is most often found in men over 60  years of age (26). 
Moreover, our results are consistent with other studies supporting 
a higher prevalence of mood disorders in this population (27, 28). 
Some studies suggest that approximately 30–40% of PD patients 
undergo depression, evidencing a strong association between 
both disorders (29). Mood disorders are, in fact, one of the most 
characteristic non-motor manifestations of PD and they could be 
experienced at stage of the disease (30, 31).
Some discrepant results emerged when examining the psycho-
logical profile of PD patients. On the one hand, previous studies 
have reported higher novelty-seeking trait scores (understood 
as a greater tendency to becoming excited about unfamiliar 
contexts) in PD patients with comorbid behavioral addictions, 
mainly gambling disorder, than in PD patients without behav-
ioral disorders (16, 32, 33). However, the significant differences 
found between the two groups in personality dimensions support 
the position that treatment-seeking patients with PD present a 
more functional personality profile than their PD-free counter-
parts. However, contrary to expectations, this study did not find 
significant differences between both groups in this personality 
TaBle 2 | Comparison between patients with and without Parkinson disorder.
Parkinson = no (n = 2,428) Parkinson = Yes (n = 32) comparison between groups
Psychiatric commorbiditiesa n % n % χ2(1) p |d|
Family history of mental disorders 1,361 56.1% 16 50.0% 0.47 0.493 0.12
History of psychiatric problems 1,000 41.2% 17 53.1% 1.86 0.173 0.24
Psychiatric disorders at present 731 30.1% 10 31.3% 0.02 0.889 0.02
Mood disorder 246 10.1% 7 21.9% 4.72 0.030* 0.32
Anxiety disorder 153 6.3% 2 6.3% 0.00 0.990 0.00
Alcohol abuse 369 15.2% 0 0% 5.72 0.017* 0.60†
Substance abuse 247 10.2% 0 0% 6.82 0.009* 0.52†
Addiction-related measuresb Mean SD Mean SD F(1; 2,445) p |d|
Age of addiction onset (years old) 28.06 11.37 46.95 12.39 87.05 0.001* 1.59†
Addiction duration (years) 13.38 7.76 13.95 9.85 0.17 0.683 0.06
Barratt Impulsiveness Scale-11 scalesb
Attentional 16.01 2.87 11.92 3.39 59.39 0.001* 1.30†
Motor 18.07 4.57 17.51 4.52 0.45 0.505 0.12
Non-planning 24.03 4.22 20.14 3.33 25.15 0.001* 1.02†
Total score 58.15 9.20 49.56 8.67 25.71 0.001* 0.96†
Temperament and Character Inventory-Revised scalesb
Novelty seeking 108.67 13.49 106.71 7.73 0.67 0.413 0.18
Harm avoidance 100.44 15.64 98.71 11.77 0.37 0.544 0.13
Reward dependence 99.21 14.38 105.53 10.12 5.74 0.017* 0.53†
Persistence 109.88 19.76 109.60 15.59 0.01 0.936 0.02
Self-directedness 128.43 20.13 136.41 17.20 4.68 0.031* 0.50†
Cooperativeness 131.84 16.27 138.11 11.62 4.43 0.035* 0.51†
Self-transcendence 63.93 14.15 63.89 9.42 0.00 0.987 0.00
aResults obtained in χ2 tests.
bResults obtained in analysis of variance.
|d|: Cohen’s-d coefficient.
Results adjusted by the participants’ age and behavioral addiction subtype.
*Bold: significant comparison (0.05 level).
†Bold: moderate (|d| > 0.50) to high (|d| > 0.80) effect size.
p-Value includes Bonferroni–Finner’s correction for multiple statistical comparisons.
4
Sauvaget et al. Behavioral Addictions and PD
Frontiers in Psychiatry | www.frontiersin.org November 2017 | Volume 8 | Article 214
dimension. On the other hand, taking the other personality dimen-
sions into account, the significant differences found between the 
two groups support the position that treatment-seeking patients 
with PD present a more functional personality profile than their 
PD-free counterparts. Higher scores in reward dependence and 
cooperativeness would indicate that these patients are tolerant 
and socially empathetic, despite the interference that PD motor 
symptomatology may cause in their social interactions. In turn, 
higher self-directedness levels would allow them to have clearer 
life goals and adaptively orient their behavior toward them (34). 
These dimensions would facilitate, among other aspects, greater 
adherence to treatment.
Moreover, evident differences in impulsivity traits appeared 
when comparing both groups: the PD group with a behavioral 
addiction showed considerably lower attentional and non-
planning impulsivity compared to PD-free patients with a 
behavioral addiction. Both these traits reflect an inability to wait 
for a reward and a rapid response style without proper premedi-
tation, traits that are commonly seen in behavioral addictions 
such as gambling disorder (35). This may appear to be a stark 
contrast to previous studies reporting that PD patients with an 
ICD present higher levels of impulsivity compared to other PD 
patients; however, it must be noted that behavioral addiction 
patients are often sociodemographically very distinct from PD 
patients (8). Therefore, our findings suggest that PD patients with 
a behavioral addiction may be more difficult to identify in clinical 
practice, especially during the initial stages of PD. As advocated 
for by other researchers, careful investigation of risk behaviors is 
needed in routine clinical settings, as these behaviors are rarely 
spontaneously reported to neurologists (9).
It is especially worth highlighting that our PD patient sample 
with a behavioral addiction presented lower levels of substance 
and alcohol use/abuse compared to the PD-free group. In the 
case of gambling disorder, for example, one meta-analysis found 
that the prevalence of a substance use disorder in gamblers was 
57.5% (36). Since PD patients are not widely thought to be at 
increased risk of substance abuse, this raises the likelihood that 
behavioral addictions in PD patients may risk going undetected if 
they are not properly screened (37). Future research should focus 
on the development of new treatment interventions taking this 
phenotype into account.
limitations
The findings of this study should be considered with certain 
drawbacks in mind. First, our study did not examine PD sever-
ity. Relatedly, cognition impairment was not assessed, and it has 
been postulated that PD patients with behavioral addictions have 
more severe frontal lobe dysfunction than PD patients without 
behavioral addictions (38, 39). Second, possibly due to higher 
awareness of this condition, the number of GD patients in our 
sample was vastly higher than the number of other behavioral 
addiction patients. Future research should include larger, more 
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balanced samples so as to overcome these limitations. In this 
same vein, all data were collected from men who sought treat-
ment and it significantly limits the generalizability of the present 
study results to women and other populations. Moreover, another 
issue that was not addressed in this study was whether the onset of 
the behavioral addiction occurred prior to- or following receiving 
PD diagnosis. Lastly, it would have been of interest to include a 
PD control group and larger sample of PD and behavioral addic-
tion patients.
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